FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to novel derivatives of diazepane of formula , where A, X, R3, R4, R5, R6, R8, R9, R10, R11, R12, R13, n and m have values, given in description and formula of invention, as well as their physiologically acceptable salts. Said compounds are antagonists of chemokine receptors CCR-2, CCR-5 and/or CCR-3 receptor and can be used in medicine as medications.
EFFECT: obtaining novel diazepane derivatives.
20 cl, 505 ex, 4 tbl
Title | Year | Author | Number |
---|---|---|---|
ORGANIC COMPOUNDS | 2007 |
|
RU2491285C2 |
BENZOXAZINYL-AMIDOCYCLOPENTYL-HETEROCYCLIC MODULATORS OF CHEMOKINE RECEPTORS | 2004 |
|
RU2301802C2 |
PYRIDINCARBOXAMIDES AS 11-BETA-HSD1 INHIBITORS | 2007 |
|
RU2451674C2 |
PYRROLOPYRIMIDINE AND PYRROLOTRIAZINE DERIVATIVES | 2005 |
|
RU2367663C2 |
PTERIDINES AS FGFR INHIBITORS | 2013 |
|
RU2702906C2 |
QUINAZOLINONE DERIVATIVES APPLICABLE AS MODULATORS OF FGFR KINASE | 2014 |
|
RU2701517C2 |
N-7 SUBSTITUTED PURINES AND PYRAZOLOPYRIMIDINES, COMPOSITIONS THEREOF AND METHODS FOR USE | 2010 |
|
RU2515541C2 |
QUINOLINES AS FGFR KINASE MODULATORS | 2012 |
|
RU2625303C2 |
SUBSTITUTED AZETHIDINONES, METHOD OF THEIR SYNTHESIS, PHARMACEUTICAL COMPOSITION AND METHOD OF PATIENT TREATMENT | 1993 |
|
RU2148056C1 |
ARYLSULPHONAMIDE CCR3 ANTAGONISTS | 2010 |
|
RU2539591C2 |
Authors
Dates
2012-01-10—Published
2007-04-11—Filed